Dr Reddy's Enters HRT Market With $32M India Acquisition

In a fresh move to expand its women’s health portfolio, Dr Reddy’s Laboratories has acquired the India trademarks of two HRT drugs from UK-based Mercury Pharma for $32.15 million.

The deal gives Dr Reddy’s full rights to the brands Progynova and Cyclo-Progynova in India, marking its entry into the growing hormone replacement therapy segment.

The acquisition strengthens Dr Reddy’s Laboratories presence in the gynecology market at a time when demand for menopause-related treatments is rising. Hormone replacement therapy, or HRT drugs, are prescribed to manage symptoms caused by estrogen deficiency, including hot flashes, mood changes, and other menopause-related conditions.

Also Read: India's Rare Disease Shift Driven by PRIP and PLI Policies

Progynova is a well-established brand in India and has built strong recall among doctors. By bringing these brands under its umbrella, the company aims to deepen its footprint in specialty and branded medicines, a segment that offers better margins and steady growth.

The transaction involves only the India trademarks and associated rights, allowing Dr Reddy’s to market and distribute the products locally. The move aligns with the company’s broader strategy to strengthen its India business and expand into focused therapy areas.

With this acquisition, Dr Reddy’s signals a sharper focus on women’s healthcare, positioning itself to tap into an underserved yet expanding market. The addition of these HRT drugs is expected to enhance its portfolio and support long-term growth in the domestic pharmaceutical space.